prikaz prve stranice dokumenta Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?
Medical Hypotheses, 161 (2022); 110801. https://doi.org/10.1016/j.mehy.2022.110801
Golčić, Marin; Simetić, Luka; Majnarić, Tea; Golčić, Goran; Herceg, Davorin

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Golčić, M., Simetić, L., Majnarić, T., Golčić, G. i Herceg, D. (2022). Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?. Medical Hypotheses, 161.. doi: 10.1016/j.mehy.2022.110801

Golčić, Marin, et al. "Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?." Medical Hypotheses, vol. 161, 2022. https://doi.org/10.1016/j.mehy.2022.110801

Golčić, Marin, Luka Simetić, Tea Majnarić, Goran Golčić i Davorin Herceg. "Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?." Medical Hypotheses 161 (2022). https://doi.org/10.1016/j.mehy.2022.110801

Golčić, M., et al. (2022) 'Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?', Medical Hypotheses, 161. doi: 10.1016/j.mehy.2022.110801

Golčić M, Simetić L, Majnarić T, Golčić G, Herceg D. Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?. Medical Hypotheses [Internet]. 04.2022. [pristupljeno 30.11.2024.];161. doi: 10.1016/j.mehy.2022.110801

M. Golčić, L. Simetić, T. Majnarić, G. Golčić i D. Herceg, "Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?", Medical Hypotheses, vol. 161, Travanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:670239. [Citirano: 30.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:670239
Podaci o radu
Naslov (engleski)Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?
AutorMarin Golčić https://orcid.org/0000-0002-3388-4813
AutorLuka Simetić
AutorTea Majnarić
AutorGoran Golčić
AutorDavorin Herceg
Autorova ustanova(Klinički bolnički centar Rijeka)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za onkologiju i radioterapiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Radioterapija i onkologija
Sažetak (engleski)
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers due to its aggressiveness and resistance to anti-cancer medications. Recent data suggest that solid tumors such as PDAC are infected with microbial agents, which can induce aggressive phenotype and metabolize chemotherapeutical agents. However, it was shown that gut microbiota can migrate to the pancreas and that fecal microbial transplantation (FMT) from longterm PDAC survivors can alter both gut and tumor microbiome, the immune response, and the growth of PDAC in a murine model. Although the effect of FMT on enhancing the immune response was exhibited in melanoma patients, there is no robust data to support the use of immunotherapy in the majority of PDAC patients, as chemotherapy remains the mainstay of treatment. Along with its direct cytotoxic effect, chemotherapy can also reduce ineffective cytokine sinks via lymphodepletion and increase translocation of the gut microbiota leading to stimulation of the immune response. However, chemotherapy requires a functional microbiota to exert those effects. We hypothesize that altering the microbiome with the FMT from the long-term PDAC survivors, combined with systemic treatment, can potentially enhance the relationship between chemotherapy, the immune system, and the microbiome. Albeit there is a lack of knowledge regarding the exact composition of the ideal donor microbiome and the optimal patient selection, due to the dismal prognosis of PDAC patients, such a trial could offer a low-risk, high-reward situation.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaMedical Hypotheses
Brojčani podacivol. 161, 110801
p-ISSN0306-9877
DOIhttps://doi.org/10.1016/j.mehy.2022.110801
URN:NBNurn:nbn:hr:184:670239
Datum objave publikacije2022-04
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S030698772200041X
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2023-01-24 07:43:34